LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.06 0.95

Buy Sell

Overview

Share price change

24h

Current

Min

1.02

Max

1.07

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+376.19% upside

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	0.11
Previous close	1.06

News Sentiment

By Acuity

26%

74%

52 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 gru 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 gru 2025, 23:51 UTC

Earnings

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 gru 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 gru 2025, 21:40 UTC

Earnings

Nike Sales Tick Up, But China Weakness Persists

18 gru 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 gru 2025, 23:37 UTC

Market Talk

Earnings

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 gru 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 gru 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 gru 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 gru 2025, 22:58 UTC

Acquisitions, Mergers, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 gru 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 gru 2025, 22:55 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:59 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

18 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 gru 2025, 21:35 UTC

Earnings

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 gru 2025, 21:31 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev Down 17% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q EPS 53c >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Apparel Rev $3.91B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Equipment Rev $550M >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q N Amer Rev $5.63B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Footwear Rev $7.66B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev $1.42B >NKE

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

376.19% upside

12 Months Forecast

Average 5 USD 376.19%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

52 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.